The US Food and Drug Administration has approved Genetech’s Avastin for treating glioblastoma, the most aggressive form of brain cancer.
This follows an earlier provisional approval in this setting under the FDA’s accelerated approval programme.
“Glioblastoma is the most common and aggressive form of brain cancer and can be very difficult to treat,” said Sandra Horning, Chief Medical Officer and Head of Global Product Development.
“Delaying disease progression and reducing the need for corticosteroids over the course of treatment are considered important goals for those impacted by this devastating disease where patients have limited treatment options.”
The treatment was granted full approval based on throughout evidence, including data from a Phase III study.
Avastin is now approved in the United States for nine distinct uses across six different types of cancer.